Article Text

  1. S.C. Smith1,
  2. C.V. Bouvier1,
  3. D. Michaeli2,
  4. R.E. Pounder1,
  5. M.E. Caplin1
  1. 1Dept of Gastroenterology, Royal Free and University College Medical School, London, UK; 2Aphton Corporation, California, USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

G17DT is a conjugate of an epitope derived from gastrin 17 linked to Diphtheria toxoid (DT). Gastrin is an autocrine growth factor in pancreatic and other GI tract cancers. In a phase II study of G17DT for advanced pancreatic cancer only 6/13 (45%) formed antibody to 100mcg of G17DT however 15/18 (83%) formed antibody to the higher dose of 250mcg. The median survival of the whole group was 7 months. Side effects were limited to mild local pain and erythema with 3 patients forming an abscess. Patients with pancreatic cancer are thought to have a suppressed immune response compared to other GI cancers.

Aim: To assess anti-DT antibody level pre and post vaccination to determine its correlation with Gastrin antibodies and relationship with immunogen side effects.

Methods: 26 of the 31 vaccinated patients had serum available. 18 had developed antibody to gastrin (G+) and 8 had not (G-). Anti-DT antibody level was determined by in-vitro tissue culture neutralisation of purified DT.

Results: 16 (88%) of the G+ group had non-protective levels of anti-DT antibody before vaccination compared with 7 (87%) of the G- group. In cases given 100mcg of G17DT and …

View Full Text